Affiliation:
1. Russian Scientific Centre of Radiology and Surgical Technologies n. a. academician A. M. Granov
Abstract
The aim of this study was to assess the safety and efficacy of treating patients with operable pancreatic cancer after preoperative intra-arterial infusion of chemotherapy combined with conformal radiation therapy in a multi-fractionation mode. Patients (n = 40) were randomized into two groups: the main one – intra-arterial infusion of chemotherapy + radiation therapy + surgery (n = 20), and control – intra-arterial infusion of chemotherapy + surgery (n = 20). Neoadjuvant therapy consisted of intra-arterial infusion of chemotherapy (chemoembolization of a pancreatic head tumor with oxaliplatin 85 mg/m2) followed by intra-arterial chemo infusion with gemcitabine 1000 mg/m2. In the main group, radiation therapy was also carried out in two fractions per day, 2 Gy with an interval of 4–6 hours, 5 days a week, up to a total dose of 50 Gy. In the main group, the lower incidence of postoperative pancreatitis and the pancreatic fistulas were statistically confirmed, the incidence of grade 2 therapeutic pathomorphisis increased, as well as the median life expectancy.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference27 articles.
1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology. 2019; 10 (1): 10–27. https://doi.org/10.14740/wjon1166
2. Ed. A. D. Kaprin, V. V. Starinsky, G. V. Petrova. The state of cancer care for the population of Russia in 2017. M.: MNIOI them. P. A. Herzen – a branch of National Medical Research Center of Radiology of the Ministry of Health of Russia, 2018. ill. 236 s.
3. Pokataev I. A., Gladkov O. A., Zagainov V. E., Kudashkin N. E., Lyadov V. K., Patyutko Yu.I. et al. Practical recommendations for drug treatment of pancreatic cancer. Malignant tumors 10.3s2–1 (2021): 487–501.
4. Ducreux M. et al. Haustermans k, Van Laethem JL, Conroy T, Aenold D: Cancer of the Pancreas: ESMO clinical practise guidelines. Annals of Oncology. 2015; (5): 56–68. https://doi.org/10.1093/annonc/mdv295
5. Tempero M. A. et al. Pancreatic Adenocarcinoma, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021; 19 (4): 439–457. https://doi.org/10.6004/jnccn.2021.0017